XALACOM 50 MCG — DIN 02246619
LATANOPROST : 50 MCG TIMOLOL (TIMOLOL MALEATE) : 5 MG · BGP PHARMA ULC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is XALACOM?
XALACOM 50 MCG contains LATANOPROST : 50 MCG TIMOLOL (TIMOLOL MALEATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02246619, held by BGP PHARMA ULC, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 24-Jul-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XALACOM used for?
Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension insufficiently responsive to beta-blockers, prostaglandins, or other IOP lowering agents.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Timolol, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
23 holders have a Canadian DIN containing Timolol, Combinations, across 50 DINs, of which 21 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 5 | 4 | DORZOLAMIDE-TIMOLOL, JAMP BRIMONIDINE/TIMOLOL, JAMP DORZOLAMIDE-TIMOLOL, JAMP-LATANOPROST/TIMOLOL, LATANOPROST / TIMOLOL | Sourceable in Canada |
| APOTEX INC | 5 | 3 | APO-BRIMONIDINE-TIMOP, APO-DORZO-TIMOP, APO-LATANOPROST-TIMOP, APO-TRAVOPROST-TIMOLOL PQ, APO-TRAVOPROST-TIMOP PQ | Sourceable in Canada |
| ELVIUM LIFE SCIENCES | 2 | 2 | COSOPT, COSOPT PRESERVATIVE-FREE | Sourceable in Canada |
| GENERIC MEDICAL PARTNERS INC | 2 | 2 | MED-DORZOLAMIDE-TIMOLOL, MED-LATANOPROST-TIMOLOL | Sourceable in Canada |
| MANTRA PHARMA INC | 2 | 2 | M-DORZOLAMIDE-TIMOLOL, M-LATANOPROST-TIMOLOL | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 2 | 2 | AZARGA, DUOTRAV PQ | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 4 | 1 | SANDOZ BRIMONIDINE / TIMOLOL, SANDOZ DORZOLAMIDE/TIMOLOL, SANDOZ LATANOPROST/TIMOLOL, SANDOZ TRAVOPROST / TIMOLOL PQ | Sourceable in Canada |
| TEVA CANADA LIMITED | 4 | 1 | ACT DORZOTIMOLOL, TEVA-DORZOTIMOL, TEVA-LATANOPROST-TIMOLOL, TEVA-LATANOPROST/TIMOLOL | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 3 | 1 | MYLAN-DORZOLAMIDE/TIMOLOL, MYLAN-LATANOPROST/TIMOLOL | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 2 | 1 | RIVA-DORZOLAMIDE/TIMOLOL, RIVA-LATANOPROST/TIMOLOL | Sourceable in Canada |
| ABBVIE CORPORATION | 1 | 1 | COMBIGAN | Sourceable in Canada |
| BGP PHARMA ULC | 1 | 1 | XALACOM | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MCG |
|---|---|
| Dosage form | SOLUTION |
| Route | OPHTHALMIC |
| Pack configuration (monograph) | 5 mL plastic ophthalmic dispenser bottle with dropper tip. Each bottle contains 2.5 mL of solution (approximately 80 drops). |
| Storage | Not explicitly detailed in provided text (Table of Contents lists section 11, but full text ends at section 8.2). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Timolol, Combinations |
|---|---|
| ATC code | S01ED51 |
| AHFS class | 52:40.08 ; 52:40.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02246619 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2246619 |
| Brand name | XALACOM |
| Generic / active ingredient | LATANOPROST : 50 MCG TIMOLOL (TIMOLOL MALEATE) : 5 MG |
| Market authorization holder | BGP PHARMA ULC |
| Health Canada schedule | Prescription |
| ATC code | S01ED51 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01ED |
| Current status | MARKETED |
| Status date | 24-Jul-2023 |
| Original market date | 2002-10-24 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
One drop in the affected eye(s) once daily. Not for initiating therapy. Systemic absorption reduced by nasolacrimal occlusion or closing eyelids for 2 minutes.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Reactive airway disease (asthma, severe COPD); sinus bradycardia, sick sinus syndrome, AV block (2nd/3rd degree) without pacemaker, overt cardiac failure, cardiogenic shock; hypersensitivity.
Warnings and precautions
May cause permanent iris color change (increased brown pigment) and eyelash changes. Risk of systemic beta-blocker effects (cardiovascular/pulmonary). Caution in diabetes and myasthenia gravis.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
21 of 50 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BRIMONIDINE-TIMOP | 0.5 % | SOLUTION | APOTEX INC | MARKETED | 02375311 |
| APO-DORZO-TIMOP | 5 MG | SOLUTION | APOTEX INC | MARKETED | 02299615 |
| APO-TRAVOPROST-TIMOP PQ | 0.5 % | SOLUTION | APOTEX INC | MARKETED | 02415305 |
| AZARGA | 0.5 % | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02331624 |
| COMBIGAN | 0.2 % | SOLUTION | ABBVIE CORPORATION | MARKETED | 02248347 |
| COSOPT | 5 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | 02240113 |
| COSOPT PRESERVATIVE-FREE | 20 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | 02258692 |
| DORZOLAMIDE-TIMOLOL | 20 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02522020 |
| DUOTRAV PQ | 0.5 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02278251 |
| JAMP BRIMONIDINE/TIMOLOL | 0.2 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02531704 |
2 · Same class — other molecules in ATC S01ED
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Timolol, Combinations | ACT DORZOTIMOLOL · AG-DORZOLAMIDE TIMOLOL · APO-BRIMONIDINE-TIMOP · APO-DORZO-TIMOP · +43 more | 50 | 21 | Yes |
| Timolol | APO-TIMOP · APO-TIMOP GEL · BETA-TIM - 0.25% LIQ · BETA-TIM - 0.5% LIQ · +20 more | 35 | 7 | Yes |
| Levobunolol | APO-LEVOBUNOLOL OPHTHALMIC SOLUTION USP 0.25% · APO-LEVOBUNOLOL OPHTHALMIC SOLUTION USP 0.5% · BETAGAN 0.5% OPHTHALMIC SOL · BETAGAN OPH SOLN 0.25% · +6 more | 16 | 0 | Not in Canada |
| Betaxolol | BETOPTIC LIQ · BETOPTIC S · NOVO-BETAXOLOL · SANDOZ BETAXOLOL | 4 | 0 | Not in Canada |
| Betaxolol, Combinations | BETOPTIC/PILO | 1 | 0 | Not in Canada |
| Levobunolol, Combinations | PROBETA - LIQ OPH | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC S01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| S01EE | Bimatoprost · Latanoprost · Latanoprostene Bunod · Tafluprost · Travoprost · +1 more | 40 | 19 |
| S01EA | Apraclonidine · Brimonidine · Dipivefrine · Epinephrine | 28 | 10 |
| S01EC | Acetazolamide · Brinzolamide · Brinzolamide, Combinations · Dorzolamide · Methazolamide | 32 | 8 |
| S01EB | Acetylcholine · Carbachol · Ecothiopate · Pilocarpine · Pilocarpine, Combinations | 65 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.